RSV Antibodies for Passive Immunization
Nirsevimab is the first-line prophylactic option for all infants, providing season-long protection through a single intramuscular dose of long-acting monoclonal antibody administered before or during RSV season 1.
The Biological Premise
RSV-specific antibodies work by binding to the prefusion conformation of the RSV fusion (F) protein, neutralizing the virus before it can infect respiratory epithelial cells. This passive immunization strategy bypasses the infant's immature immune system, providing immediate protection from birth through the highest-risk period (first 2-3 months of life when RSV hospitalization rates peak) 2, 3.
The key advantage over active vaccination is that infants lack the immunological maturity to mount robust vaccine responses, making passive antibody transfer the only viable early-life protection strategy 2.
First-Line Prophylaxis: Nirsevimab
ACIP recommends nirsevimab for:
- All infants <8 months born during or entering their first RSV season
- Children 8-19 months at increased risk for severe RSV disease entering their second season 1
Dosing and Timing
- Single intramuscular injection
- Administer October through March in most continental U.S. regions (adjust based on local RSV seasonality)
- Extended half-life provides season-long protection without repeat dosing 1, 4
Advantages Over Palivizumab
Nirsevimab represents a paradigm shift from palivizumab (the older monoclonal antibody), which required monthly injections and was restricted to high-risk infants only. Nirsevimab's extended half-life and universal recommendation make it operationally superior 2, 4.
Second-Line/Historical Option: Palivizumab
Palivizumab remains an option but is now largely superseded. Its 2014 AAP guidance restricted use to:
- Infants born <29 weeks gestation and <12 months at RSV season start
- Infants with chronic lung disease requiring ongoing medical support
- Select infants with hemodynamically significant congenital heart disease 5
Common pitfall: Palivizumab requires monthly dosing throughout RSV season, leading to compliance challenges and gaps in protection—a problem eliminated by nirsevimab's single-dose regimen.
Emerging Strategy: Maternal RSV Vaccination
FDA-approved maternal RSVpreF vaccine (administered 32-36 weeks gestation) provides an alternative passive immunization route through transplacental antibody transfer 3.
Key Considerations for Maternal Vaccination
- Only effective if delivery occurs during RSV season
- Protection begins at birth but wanes over time due to antibody catabolism
- Less effective when vaccination occurs shortly before delivery (insufficient time for antibody transfer)
- CDC recommends maternal vaccination OR infant nirsevimab—not both routinely 3
Comparative Advantages
- Nirsevimab: Standardized protection regardless of gestational age, maternal immune status, or timing; particularly valuable for preterm infants 6
- Maternal vaccination: Integrates into existing antenatal care; may be more cost-effective in settings with robust prenatal care access 6
Special Populations
Immunocompromised Children
Prophylaxis may be considered for profoundly immunocompromised children <24 months during RSV season, though efficacy data are limited 5. Nirsevimab is preferred over palivizumab due to single-dose convenience.
Post-Cardiac Surgery
Critical caveat: Cardiopulmonary bypass reduces palivizumab concentrations by 58%. For children requiring ongoing prophylaxis post-surgery, redosing considerations apply 5. This is less relevant with nirsevimab's extended half-life, but monitoring remains prudent.
Implementation Algorithm
- All infants <8 months entering RSV season: Administer nirsevimab 1
- Pregnant patients 32-36 weeks gestation with anticipated RSV season delivery: Offer maternal RSVpreF vaccine IF nirsevimab not planned for infant 3
- High-risk children 8-19 months (second RSV season): Administer nirsevimab if chronic lung disease, congenital heart disease, or profound immunocompromise 1
- Timing: Begin administration in October; adjust based on local RSV epidemiology 1
Evidence Quality Note
The 2023 ACIP nirsevimab recommendations 1 represent the highest-quality, most recent guideline evidence and supersede the 2014 palivizumab guidance 5 for the general infant population. The shift reflects both improved antibody technology (extended half-life, prefusion F protein targeting) and recognition that universal prophylaxis is cost-effective given RSV's substantial disease burden across all infants, not just traditional high-risk groups 2, 7.